Stock Track | Tango Therapeutics Plummets 10.11% Intraday Following Analyst Rating Downgrade

Stock Track05-15

Tango Therapeutics Inc. (TNGX) plummeted 10.11% during intraday trading on Friday, as the stock faced significant selling pressure.

The sharp decline followed a series of analyst rating actions, most notably Piper Sandler's downgrade of the stock to Neutral from Overweight, despite simultaneously raising its price target to $24 from $16. Other analyst moves included Leerink Partners raising its target price to $55 from $28 and Mizuho increasing its target to $30 from $20.

The market reaction suggests that the downgrade in rating from Piper Sandler outweighed the positive target price adjustments from other firms, reflecting a shift in sentiment towards the biotechnology company's near-term prospects.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment